Fig. 2From: Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosisChanges in bone marrow fibrosis grade during ruxolitinib (RUX) therapy and best available therapy (BAT). Individual changes were calculated as a worsening (cases with baseline BM fibrosis grade 3 were excluded from this analysis because further progression is not defined), b improvement, or c improvement or stabilizationBack to article page